<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122287</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SDU-QILU-G709</org_study_id>
    <nct_id>NCT04122287</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin</brief_title>
  <official_title>Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the effectiveness of
      levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple
      regimens for the primary treatment of Helicobacter pylori infection in patients allergic to
      penicillin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori(H.pylori), which infects about 50% of the global population, has been
      recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac
      gastric cancer. Strongly evidence supports that H.pylori eradication is an effective approach
      to reduce the incidence of those pathologies.However,Helicobacter pylori eradication is a
      challenge in patients allergic to penicillin.

      Therefore, the investigators aim to assess and compare the effectiveness of
      levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple
      regimens for the primary treatment of Helicobacter pylori infection in patients allergic to
      penicillin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rates in 2 groups</measure>
    <time_frame>24 months</time_frame>
    <description>Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of improving dyspepsia symptoms after Helicobacter pylori eradication</measure>
    <time_frame>24 months</time_frame>
    <description>Dyspepsia symptoms will be measured using a 8-point Likert scale, and patients rate their symptoms from 0 (none) to 8 (severe) before and after the Helicobacter pylori eradication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of adverse events happening</measure>
    <time_frame>24 months</time_frame>
    <description>Similarly, adverse events will also be measured by the Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of good compliance</measure>
    <time_frame>24 months</time_frame>
    <description>Patients taken over 90% of drugs are considered to have a good compliance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>levofloxacin-tetracycline-containing quadruple group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tinidazole-tetracycline-containing quadruple group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>levofloxacinn-tetracycline-containing quadruple regimens</description>
    <arm_group_label>levofloxacin-tetracycline-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinidazole</intervention_name>
    <description>tinidazole-tetracycline-containing quadruple regimens</description>
    <arm_group_label>tinidazole-tetracycline-containing quadruple group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-70 with H. pylori infection.

          -  Patients Allergic to Penicillin.

        Exclusion Criteria:

          -  Patients with previous H. pylori eradication therapy.

          -  Patients treated with Histamine-receptor antagonist, proton pump inhibitor, bismuth
             and antibiotics in the previous 4 weeks.

          -  Patients with gastrectomy, acute gastrointestinal bleeding and advanced gastric
             cancer.

          -  Patients with known or suspected allergy to study medications.

          -  Currently pregnant or lactating.

          -  Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, PhD,MD</last_name>
    <phone>15588818685</phone>
    <phone_ext>053188369277</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, PhD,MD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiuli Zuo, PhD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minjuan Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Allergic</keyword>
  <keyword>Penicillin</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Eradication</keyword>
  <keyword>Tetracycline</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

